Harrow to Participate in Three Investor Conferences in September

NASHVILLE, Tenn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following three investor conferences in September in New York, NY: 2026 Cantor Global Healthcare Conference Format: Fireside chat + 1x1 investor meetings Date/Time: Wednesday, September 9, 2026, at 1:35 p.m.

GlobeNewsWire • Sep 1, 2026

Harrow's Iheezo Cuts Eye-Injection Discomfort by More Than Half

Ophthalmic disease management company Harrow Inc. (NASDAQ:HROW) on Thursday shared outcomes from a prospective, randomized, contralateral-eye clinical study.

Benzinga • Aug 21, 2026

Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections

Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest

GlobeNewsWire • Aug 20, 2026

Harrow: The Q2 Turnaround Is Enough For A Cautious Buy

Harrow is upgraded from Hold to a cautious Buy, driven by Q2 executional improvements and better visibility on operating leverage. VEVYE's revenue and economics have improved, while IHEEZO delivered record demand despite reimbursement headwinds, supporting the growth thesis. I model $490M in 2027 revenue and a 4.5x EV/sales multiple, yielding a $52 price target—about 33% upside from current levels.

Seeking Alpha • Aug 13, 2026

Harrow Q2 Earnings Call Highlights

Harrow NASDAQ: HROW reported second-quarter revenue of $70.7 million, up 11% from a year earlier and about 60% sequentially, as the ophthalmic pharmaceutical company said it entered the second half of 2026 with stronger demand across several products, improved pricing and expanded commercial infrastructure.

MarketBeat • Aug 11, 2026

Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript

Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 11, 2026

Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates

Harrow (HROW) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.24 per share a year ago.

Zacks Investment Research • Aug 11, 2026

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

NASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company.

GlobeNewsWire • Aug 6, 2026

Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026

Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 11, 2026 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 11, 2026

GlobeNewsWire • Jul 27, 2026

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three studies supporting IHEEZO® (chloroprocaine HCl ophthalmic gel 3%), a broadly labeled low viscosity ocular anesthetic gel, and BYOOVIZ® (ranibizumab-nuna)i, an FDA-approved biosimilar referencing LUCENTISii (ranibizumab) at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting. Collectively, the presentations expand the growing body of clinical and real-world evidence supporting Harrow's retina portfolio and reinforce Harrow's commitment to generating quality evidence that strengthens physician confidence, improves patient experience, and supports long-term product adoption and innovation.

GlobeNewsWire • Jul 20, 2026